Blockchain Registration Transaction Record

Feeder-Free TIL Therapy Cuts IL-2 Dependence, Boosts Safety

New feeder-free TIL protocol reduces IL-2 dependence and enhances safety in adoptive cell therapy for solid tumors, combining with PD-1 blockade for improved efficacy.

This research matters because it directly addresses the biggest barriers to TIL therapy: toxicity from high-dose IL-2 and complex manufacturing. By eliminating feeder cells and reducing IL-2, the protocol could make TIL therapy safer, cheaper, and more widely available for patients with solid tumors like melanoma, colorectal, and pancreatic cancers. If validated in humans, it could expand access to a potentially curative immunotherapy beyond specialized centers.